Comparative Pharmacology
Head-to-head clinical analysis: LANSOPRAZOLE versus PRILOSEC OTC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANSOPRAZOLE versus PRILOSEC OTC.
LANSOPRAZOLE vs PRILOSEC OTC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that inhibits gastric acid secretion by binding to the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, preventing the final step of acid production.
Proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, suppressing gastric acid secretion.
15-30 mg orally once daily; 30 mg IV over 30 minutes once daily (when oral not possible).
20 mg orally once daily for 14 days for frequent heartburn; may repeat 14-day course every 4 months.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (increased to 3-6 hours in elderly, hepatic impairment).
Clinical Note
moderateDexlansoprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateLansoprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Lansoprazole."
Clinical Note
moderateDexlansoprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateApproximately 0.5–1 hour in healthy subjects; longer (up to 3 hours) in slow metabolizers or hepatic impairment. Clinically, the duration of acid suppression exceeds the half-life due to accumulation in parietal cell canaliculi.
Renal (14-23% as metabolites); biliary/fecal (major route, ~60% as metabolites and parent drug).
Primarily hepatic metabolism; about 80% of metabolites are excreted in urine, and the remainder in feces via bile. Less than 1% of unchanged drug is excreted in urine.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor
Lansoprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Lansoprazole."